Discovery Park selects 13 start-ups to join Discovery Spark life science programme

The 8-week programme offers in person training from industry leaders to build strong business foundations and prepare for investment. The Discovery Spark programme will equip the early-stage companies with the necessary skills to catalyse their business growth plans and gives them the chance to win a business support package worth over £100,000.

Finalists have the chance to win a business support package worth over £100,000, including one year of free lab space at Discovery Park and £50,000 investment from Discovery Park Ventures. The winner will be announced at the GIANT Health conference on 5th December 2023. 

The start-ups span across the biotech, digital tech, engineering biology, synthetic biology and medical technology sectors. Participants were chosen by a judging panel that scored the start-ups based on their product or service, opportunity and market, team management, programme fit and investment potential. Taking part in the programme will be 3D Synthesis, Awen, Bing Bong Biologics, BioMavericks, BugBiome, CardioCrown, DLOC Biosystems, Dravya Discovery, KASNMR, Matrix Bio, Rapidx Bio, The Future Care and XR-Musica.

As part of the programme, Discovery Park will host in-person training sessions, covering topics such as building an excellent team, understanding and conveying business metrics, and branding. The start-ups will also be able to take advantage of opportunities for networking, mentoring, learning from shared experiences and perfecting their investor pitch. The programme will culminate with an investor pitching event sponsored by Discovery Park as part of the GIANT Health conference on 5th December 2023. The start-up with the best pitch at the conference will win a business support package worth over £100,000. The package includes one free year of lab space at Discovery Park and £50,000 investment from Discovery Park Ventures, as well as comprehensive business support and mentoring.

Discovery Park’s Head of Innovation, Renos Savva, is leading the programme, bringing extensive experience in science entrepreneurship including co-founding Domainex and providing training for life science audiences across academia and industry. He said: “We were overwhelmed by the number of applications for Discovery Spark. The start-ups selected show phenomenal potential and we’re excited to accelerate their growth. Being investor-ready is essential for start-ups and Discovery Spark ensures participants will have the best team, brand image and business know-how by the end of the programme.”

BugBiome is harnessing the power of the skin microbiome to repel mosquitoes. Most mosquito repellents on the market provide protection for just a few hours and contain persistent synthetic chemicals that can harm the environment. BugBiome aims to utilise natural bacteria that repel mosquitoes to create an effective and safe solution. Alicia Showering, Founder and CEO at BugBiome, said: “We’re passionate about stopping the spread of deadly vector-borne diseases like malaria and Dengue by bringing longer-lasting natural repellents to market. Taking part in Discovery Spark will give us the necessary business tools to make this a reality.”

Delayed diagnosis of microbial diseases leads 15 million avoidable deaths every year. RapidX has developed a disease detection technology to deliver point of care diagnosis in under 30 minutes. Its technology doesn’t require specialist training to use and has important implications for the targeted treatment of diseases which will be vital to combat microbial drug resistance.

CardioCrown develops MedTech devices that empower stroke rehabilitation at home. Its integrated rehabilitation technology incorporates virtual reality, functional electrical stimulation and artificial intelligence to help accelerate the recovery of stroke patients. The engaging product will also reduce the time clinicians will have to spend with patients and help stroke units streamline processes.

Mayer Schreiber, CEO at Discovery Park, commented: “Not only will participants receive business training fine-tuned to life-science start-ups, but also access to Discovery Park’s cutting-edge facilities, where they will have the opportunity to network, ideate and collaborate. Discovery Park is committed to supporting the next generation of life science leaders, and our Discovery Spark programme embodies that.”
 

More news and updates 

ACROBiosystems launches the world’s first GMP-grade DLL-4 Protein

ACROBiosystems, a global cornerstone of the pharmaceutical industry committed to offering innovative tools and solutions, announces the launch of GMP grade DLL4. GMP grade DLL4 is the first recombinant Delta-like Ligand 4, or DLL4, to be launched on the market under GMP conditions.

Investors-in-residence join Cancer Research Horizons to advance Ventures team

Jonathan Tobin, a partner at life science venture capital firm Brandon Capital, and Genghis Lloyd-Harris, a senior advisor at life sciences investment firm, Abingworth, have joined Cancer Research Horizons’ Ventures team as advisory investors-in-residence.

Milner, AstraZeneca, and MRC partner for functional genomics advancements

The University of Cambridge announced a new partnership with AstraZeneca and the Medical Research Council (MRC) that will establish a new state-of-the-art functional genomics laboratory at the Milner Therapeutics Institute.

RoslinCT to manufacture world’s-first CRISPR-based therapy

RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration

Rosalind Franklin Institute appoints Professor Paul Matthews as new director

The Rosalind Franklin Institute announces Professor Paul Matthews as its new Institute Director. Professor Matthews is a world class clinician scientist with over 30 years of experience working on neurodegenerative disorders.

Brainomix expands to the US with FDA-cleared Stroke AI Platform

Brainomix, the AI-powered medtech solutions company, has heralded its continued US expansion with the launch of its full suite of FDA-cleared modules in its Brainomix 360 platform for stroke care.

Cancer Research Horizons opens nominations for its Innovation & Entrepreneurship Awards 2024

Cancer Research Horizons, the innovation arm of Cancer Research UK, has opened nominations for its Innovation & Entrepreneurship Awards 2024, which celebrate the UK’s most enterprising efforts in oncology.

Merit reaches key project milestone for Moderna's clinical laboratories

Northumberland-headquartered Merit, the UK’s leading industrialised construction and digital manufacturing specialist, has reached a significant project milestone for Moderna’s clinical laboratories project.

PrecisionLife announces new appointments to launch diagnostics and healthcare strategy

PrecisionLife® announces the appointment of Dr Gerald Dunstan as SVP Corporate Development and Hannah Bibby as Product Strategy Lead to drive the company’s expansion into precision diagnostics and personalized healthcare.

Touchlight’s DNA used in the manufacture of Versameb’s VMB-100 in first human clinical study

Touchlight's proprietary doggybone DNA (dbDNA) has been used as a critical starting material for manufacturing of VMB-100, a potency enhanced messenger ribonucleic acid (mRNA) encoding human insulin-like growth factor-1 (IGF-1) to support Versameb’s first-in-human clinical study to treat chronic stress urinary incontinence (SUI).

 

More within